Q&A with Schenk AccuRate's Chad Lorensen - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Schenk AccuRate's Chad Lorensen
Lorensen discusses client demands and industry trends.

Pharmaceutical Technology
Volume 34, Issue 5, pp. 86

Q & A with
Chad Lorensen, pharmaceutical industry business-development manager of Schenck AccuRate



PharmTech:
What is the biggest industry challenge you're now facing?

Lorensen
The development of continuous manufacturing processes. We are monitoring, helping where we can, and working with companies in the pharmaceutical industry who are studying continuous manufacturing processes for solid dosage products. Our core products have the strengths that provide value for this type of manufacturing process.

PharmTech:
How do you stay abreast of new developments in the industry?

Lorensen
Schenck stays abreast of the latest industry developments through regular communication with our customers, developing strong working relationships with other pharmaceutical-industry equipment manufacturers, and by participating in research consortiums at various universities. Further information is gathered by reviewing various pharmaceutical periodicals and attending trade show exhibitions. In addition, Schenck is a global company, and each of its offices can share ideas with other Schenck locations throughout the world.

PharmTech:
Do you see a new industry trend emerging?

Lorensen
We are looking forward to the pharmaceutical industry's acceptance of continuous mixing, granulation, and hot-melt extrusion.

PharmTech:
What is the most common demand your clients are currently making of you?

Lorensen
The most common request is to provide equipment to customers' sites for trials and experiments made in conjunction with other types of continuous processing equipment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here